Dyslipidemia: Pathogenesis and Management

  • Patricia Freitas CorradiEmail author
  • Nidhi Agrawal
  • Namrata Gumaste
  • Ira J. Goldberg
Reference work entry


The major cause of mortality in patients with both type 1 and type 2 diabetes is cardiovascular complications. Much of this might be attributed to changes in circulating levels of atherogenic and antiatherogenic lipoproteins. An atherogenic profile in patients with type 2 diabetes is termed diabetic dyslipidemia. Lifestyle and medical therapies can be used to treat this condition, leading to major changes in circulating lipids. In this chapter, we review the causes, therapies, and changes in outcomes due to treatment of hyperlipidemias in patients with diabetes.


Hyperlipidemia Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Low Density Lipoproteins (LDL) Cardiovascular Disease (CVD) Triglycerides Cholesteryl Esters Very Low Density Lipoproteins (VLDL) High Density Lipoprotein (HDL) Chylomicrons Apolipoprotein B (apoB) Lipoprotein Lipase (LpL) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Pancreatitis Statins Ezetimibe Niacin PCSK9 Inhibitors Fibric Acid 


  1. 1.
    Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care. 1991;14(9):839–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86(3):965–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272(2):185–96.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21(1):160–78.CrossRefPubMedGoogle Scholar
  5. 5.
    Eckel RH, Albers JJ, Cheung MC, Wahl PW, Lindgren FT, Bierman EL. High density lipoprotein composition in insulin-dependent diabetes mellitus. Diabetes. 1981;30(2):132–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Wilson DE, Hata A, Kwong LK, Lingam A, Shuhua J, Ridinger DN, et al. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes. J Clin Invest. 1993;92(1):203–11.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37:249–73.PubMedGoogle Scholar
  8. 8.
    Writing Group for the DERG, Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313(1):45–53.CrossRefGoogle Scholar
  9. 9.
    Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia. 1978;14(6):363–70.CrossRefPubMedGoogle Scholar
  10. 10.
    Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes. 1984;33(3):271–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81(9):1158–62.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–86.Google Scholar
  13. 13.
    American DA. Standards of medical care in diabetes – 2014. Diabetes Care. 2014;37 Suppl 1:S14–80.CrossRefGoogle Scholar
  14. 14.
    Maahs DM, Daniels SR, de Ferranti SD, Dichek HL, Flynn J, Goldstein BI, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014;130(17):1532–58.CrossRefPubMedGoogle Scholar
  15. 15.
    Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case–control study. Diabetes Care. 2009;32(3):416–20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006;35(3):491–510. vii-viii.CrossRefPubMedGoogle Scholar
  17. 17.
    Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab. 2013;24(8):391–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes. Best Pract Res Clin Endocrinol Metab. 2014;28(3):325–38.CrossRefPubMedGoogle Scholar
  19. 19.
    Boyne MS, Saudek CD. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care. 1999;22 Suppl 3:C45–53.PubMedGoogle Scholar
  20. 20.
    Nikkila EA, Hormila P. Serum lipids and lipoproteins in insulin-treated diabetes. Demonstration of increased high density lipoprotein concentrations. Diabetes. 1978;27(11):1078–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Costacou T, Evans RW, Orchard TJ. High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol. 2011;5(5):387–94.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Verges B. Lipid disorders in type 1 diabetes. Diabetes Metab. 2009;35(5):353–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Kurisu S, Iwasaki T, Ishibashi K, Mitsuba N, Dohi Y, Nishioka K, et al. Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease. J Renin Angiotensin Aldosterone Syst. 2013;14(1):51–5.CrossRefPubMedGoogle Scholar
  24. 24.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004;26(5):744–54.CrossRefPubMedGoogle Scholar
  26. 26.
    Podolsky S, Burney SW. Effects of long term sulfonylurea therapy on plasma insulin and fasting lipid levels. Diabete Metab. 1979;5(2):113–7.PubMedGoogle Scholar
  27. 27.
    Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1):14–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Sun F, Wu S, Wang J, Guo S, Chai S, Yang Z, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225–41. e8.CrossRefPubMedGoogle Scholar
  29. 29.
    Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009;18(10):1495–503.CrossRefPubMedGoogle Scholar
  30. 30.
    Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53(3):552–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab. 2014;28(3):423–37.CrossRefPubMedGoogle Scholar
  33. 33.
    Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol. 2011;31(8):1716–25.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Tonkin A, Hunt D, Voysey M, Kesaniemi A, Hamer A, Waites J, et al. Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Am Heart J. 2012;163(3):508–14.CrossRefPubMedGoogle Scholar
  35. 35.
    Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260(5):641–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Rubins HB, Robins SJ, Collins D. The veterans affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol. 1996;78(5):572–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74.CrossRefGoogle Scholar
  39. 39.
    Fruchart JC, Sacks FM, Hermans MP. International Steering Committee of R. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010;26(8):1793–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905–10.Google Scholar
  41. 41.
    Guyton JR. Combination drug therapy for combined hyperlipidemia. Curr Cardiol Rep. 1999;1(3):244–50.CrossRefPubMedGoogle Scholar
  42. 42.
    Milone M, Lupoli R, Maietta P, Di Minno A, Bianco P, Ambrosino P, et al. Lipid profile changes in patients undergoing bariatric surgery: a comparative study between sleeve gastrectomy and mini-gastric bypass. Int J Surg. 2015;14:28–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Patricia Freitas Corradi
    • 1
    Email author
  • Nidhi Agrawal
    • 2
  • Namrata Gumaste
    • 2
  • Ira J. Goldberg
    • 3
  1. 1.Division of EndocrinologyNew York University (NYU)New YorkUSA
  2. 2.School of MedicineNew York UniversityNew YorkUSA
  3. 3.NYU Division of Endocrinology, Diabetes, and MetabolismNYU School of MedicineNew YorkUSA

Personalised recommendations